The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human ...

Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date set for July 17, 2026. The drug is intended for HR+/HER2–, PIK3CA wild-type ...

Jones spoke to MHE after presenting research at the 2026 ASCO Gastrointestinal Cancers Symposium, held Jan. 8-10, in San ...

FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026MINNEAPOLIS, (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: ...

GLP-1 receptor agonists (GLP-1Ras) significantly outperformed Aspirin (acetylsalicylic acid) in reducing the risk of colorectal cancer, regardless of a patient’s weight or diabetes status, according ...

Roche expects filing for up to three new molecular entities in 2026, and accelerating its pipeline through partnerships and ...

GLP-1 receptor agonists may be superior to aspirin for primary prevention of colorectal cancer, according to study results ...

Furthermore, GLP-1 drugs had a favorable safety profile versus aspirin, particularly with respect to bleeding events, said ...

The intricate link between endocrine disorders and cancer development has drawn significant interest, revealing how ...

Alshehri, E. (2026) The Diagnostic Conundrum of Recurrent High-Grade Vaginal Intraepithelial Neoplasia (VAIN) Following ...

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of ...